Drug Trial Radar · NCT06297603
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
341
Actual
Start
Mar 15, 2024
Primary completion
Oct 26, 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Mar 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.
Conditions
- Type 2 Diabetes
Interventions
RetatrutideDrug
Administered SC
PlaceboDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Hemoglobin A1c (HbA1c) (%)Time frame: Baseline, Week 52
Locations
76 sites in 7 countries. Site status is shown where the registry gives one.
Nephrology Consultants
Huntsville, Alabama
Clinical Research Institute of Arizona (CRI) - Sun City West
Sun City West, Arizona
Kidney & Hypertension Center - Apple Valley
Apple Valley, California
Hope Clinical Research, Inc.
Canoga Park, California
Neighborhood Healthcare Institute of Health
Escondido, California
EndoTrials Center for Clinical Research
La Mesa, California
UCLA South Bay Endocrinology
Torrance, California
Northeast Research Institute (NERI)
Fleming Island, Florida
Encore Medical Research - Weston
Weston, Florida
Orita Clinical Research
Decatur, Georgia
CARE Institute
Idaho Falls, Idaho
Cotton O'Neil Diabetes & Endocrinology
Topeka, Kansas
Billings Clinic
Billings, Montana
Excel Clinical Research, LLC
Las Vegas, Nevada
Albany Medical College, Division of Community Endocrinology
Albany, New York
NYC Research INC
Long Island City, New York
Research Foundation of SUNY - University of Buffalo
Williamsville, New York
University of North Carolina Medical Center
Chapel Hill, North Carolina
Central States Research
Tulsa, Oklahoma
Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair
Pittsburgh, Pennsylvania
AM Diabetes & Endocrinology Center
Bartlett, Tennessee
Velocity Clinical Research, Dallas
Dallas, Texas
Prime Revival Research Institute, LLC
Flower Mound, Texas
Juno Research
Houston, Texas
PlanIt Research, PLLC
Houston, Texas
Southern Endocrinology Associates
Mesquite, Texas
Texas Valley Clinical Research
Weslaco, Texas
Diabetes & Endocrine Treatment Specialists
Sandy City, Utah
Investigaciones Medicas Imoba Srl
Buenos Aires, Argentina
Centro de Investigaciones Metabólicas (CINME)
Buenos Aires, Argentina
CIPREC
Buenos Aires, Argentina
CIPREC
Buenos Aires, Argentina
Centro Médico Viamonte
Buenos Aires, Argentina
Mautalen Salud e Investigación
Buenos Aires, Argentina
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
Buenos Aires, Argentina
CEDIC
CABA, Argentina
Centro Diabetológico Dr. Waitman
Córdoba, Argentina
Centro Médico Colón
Córdoba, Argentina
Centro de Investigaciones Clínicas Baigorria
Granadero Baigorria, Argentina
CIMeL
Lanus, Argentina
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.